Approval cements daratumumab as a foundational therapy in newly diagnosed multiple myeloma and the only anti-CD38 antibody for all patient types in this setting  Phase 3 CEPHEUS study shows significant improvement in minimal residual disease (MRD)-negativity rate, progression-free survival and complete response or better versus standard of care1 Beerse, Belgium, April 07, 2025 (GLOBE NEWSWIRE) -- Janssen-Cilag International NV, a Johnson & Johnson company, today announced that the European Commission (EC) ...

TREMFYA® demonstrated clinically meaningful and statistically significant efficacy in patients with active psoriatic arthritis at risk for structural damage in Phase 3b study Topline results demonstrate efficacy across multiple domains at Week 24, reinforcing TREMFYA® as a first-line treatment option for patients with active psoriatic arthritisSPRING HOUSE, Pa., April 4, 2025 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced that the TREMFYA® (guselkumab) Phase 3b APEX study achieved both its pr ...

Johnson & Johnson (JNJ) and Pfizer (PFE) are two of the world’s largest pharmaceutical companies with diversified healthcare portfolios. J&J operates through pharmaceuticals and medical devices divisions. In Pharmaceuticals, it has one of the most diverse revenue streams in the industry, covering a broad range of areas such as neuroscience, cardiovascular and metabolism, immunology, oncology, pulmonary hypertension and infectious diseases. On the other hand, Pfizer holds a leading position in the oncology s ...

Shares of Johnson & Johnson JNJ are trading higher on Wednesday. Yesterday, they were down more than 7.5%.  Analysts attribute the move lower to the company's announcement that its pending acquisition of Intra-Cellular Therapies, Inc. ITCI will dilute its earnings.But the sell-off may have ended, and there is a good chance Johnson & Johnson rallies. This is why our team of trading experts has made it our Stock of the Day.You can see on the chart below that the selloff ended when the shares reached the $153 ...

There are tens of thousands of claimants and a majority would have needed to vote to accept the proposed settlement, which J&J claims it had. The judge said, however, that the "unreasonably short voting time" made the votes suspect and that at least half of the votes "cannot count." This marks the third time Johnson & Johnson's bankruptcy strategy has failed in court. Shares of Johnson & Johnson (JNJ -6.68%) are tumbling on Tuesday. The company's stock lost 6.3% as of 2:25 p.m. ET. The drop comes as the S&P ...

About this content About Emily Jarvie Emily began her career as a political journalist for Australian Community Media in Hobart, Tasmania. After she relocated to Toronto, Canada, she reported on business, legal, and scientific developments in the emerging psychedelics sector before joining Proactive in 2022. She brings a strong journalism background with her work featured in newspapers, magazines, and digital publications across Australia, Europe, and North America, including The Examiner, The Advocate, The ...

A US bankruptcy judge on Monday rejected Johnson & Johnson's $10 billion proposal to end tens of thousands of lawsuits alleging that its baby powder and other talc products cause ovarian cancer, marking the third time the company's bankruptcy strategy has failed in court. J&J has been attempting to resolve the lawsuits through a subsidiary company's bankruptcy, after two previous bankruptcy attempts failed in other courts. But the judge overseeing its case, US Bankruptcy Judge Christopher Lopez in Houston, ...

J&J faces more than 62,000 lawsuits for its talc-based products, primarily its baby powders. The lawsuits allege that its talc products contain asbestos, which caused many women to develop ovarian and some other cancers. J&J insists that talc-based products are safe and do not cause cancer. J&J has permanently discontinued the sale of its talc-based Johnson's Baby Powder globally. J&J's 3 Bankruptcy Filing in Texas After Two Failed Attempts In September, J&J, via a subsidiary called Red River Talc, filed fo ...

Recent Developments Related to JNJ's Rybrevant J&J (JNJ) recently reported new positive data from the phase III MARIPOSA study, which compared the combination of Rybrevant and Lazcluze against AstraZeneca's (AZN) Tagrisso in first-line EGFR-mutated non-small cell lung cancer ("NSCLC"). Data from the study suggests that the Rybrevant-Lazcluze combo significantly extends overall survival ("OS") in NSCLC patients with EGFR exon 19 deletions (ex19del) or exon 21 L858R substitution (L858R) mutations. At a median ...

Core Insights - The article discusses a comparative analysis between AbbVie and Johnson & Johnson, suggesting that Benjamin Graham would favor Johnson & Johnson due to its consumer healthcare segment [1]. Group 1 - Johnson & Johnson stock (NYSE: JNJ) was the focus of a previous analysis published on February 19, 2025 [1]. - The analysis highlighted the strengths of Johnson & Johnson in the consumer healthcare market compared to AbbVie [1].